The GRAS Loophole: How Additives Skip FDA Review

What GRAS Actually Means in Regulatory Terms

GRAS is a regulatory classification, not a safety guarantee. According to the FDA, a food substance qualifies as GRAS when it has a long history of safe use in food or when competent experts have concluded it is safe based on scientific data (FDA, 2018). The threshold for GRAS differs significantly from the formal food additive approval process.

When the FDA formally approves an additive, manufacturers must submit detailed toxicology studies, animal and sometimes human data, and proposed usage limits. The agency reviews this evidence and makes an explicit determination. With GRAS, however, companies can rely on published scientific literature, industry consensus, and historical use without submitting a formal petition to the FDA.

The distinction matters: GRAS is a legal category that permits an ingredient to be used without prior FDA authorization. It is not a statement that the FDA has independently verified safety. Many GRAS substances are genuinely safe—salt, sugar, and vinegar are GRAS—but the pathway does not guarantee the same level of scrutiny as the formal approval process.

The History of GRAS: From Common Sense to Regulatory Shortcut

GRAS emerged from the Food Additives Amendment of 1958, which required pre-market approval for new food additives. However, Congress recognized that hundreds of substances had been safely used in food for decades or centuries before the amendment. Requiring formal approval for salt, pepper, and cinnamon would be impractical and unnecessary.

So GRAS was created as a grandfather clause for substances already in common use (FDA, 2016). Initially, the FDA maintained a list of GRAS substances and evaluated them. But in 1997, the FDA introduced the Voluntary GRAS Notification Program, which shifted responsibility to manufacturers. Companies could now assess whether their ingredient met GRAS criteria and notify the FDA—or skip notification entirely and self-determine GRAS status.

This 1997 shift fundamentally changed how GRAS functioned. Instead of the FDA pre-screening all GRAS claims, companies began conducting in-house reviews and proceeding without federal input. The FDA estimates that only about 50% of GRAS determinations are formally notified to the agency (FDA, 2016). The other half—hundreds of substances—exist in a legal gray zone: used as if they are GRAS but never officially vetted by regulators.

How Companies Self-Certify GRAS Status Without FDA Pre-Approval

The current GRAS process allows manufacturers considerable autonomy. Here is the typical pathway:

Step 1: In-House Scientific Review.A company identifies an additive it wants to use and assembles or hires experts to review available literature, animal studies, and historical use data. This review is conducted by the manufacturer's own team or contracted consultants with financial interest in approval.

Step 2: Optional FDA Notification. The company may send a GRAS notice to the FDA describing the substance, proposed use, and safety rationale. The FDA has 90 days to raise questions; silence is often interpreted as acceptance, though the FDA explicitly states it does not confirm GRAS status through this process.

Step 3: Market Entry Without Confirmation. If a company chooses not to notify the FDA, or after notification passes without objection, the ingredient can be used in food immediately. The manufacturer relies on self-determination that the substance is GRAS.

This contrasts sharply with formal additive approval, which requires FDA authorization before market use. A Government Accountability Office report found that the FDA challenges only a small fraction of GRAS notices—fewer than 1% result in substantive FDA objections (GAO, 2010). The practical outcome is that most notified GRAS substances proceed to market.

The Role of GRAS Expert Panels

Companies often assemble panels of food safety experts to evaluate GRAS claims. While these panels may include respected scientists, they are selected and funded by the manufacturer. The panel reviews data and publishes a conclusion that the substance is GRAS. These expert determinations carry weight but are not independent; the experts' conclusions reflect the evidence selected and framed by the company seeking approval.

Notable Examples: Additives That Sidestepped Full FDA Review

Several widely used additives have entered the market or expanded use through GRAS determinations rather than formal approval:

Partially Hydrogenated Oils (PHOs). For decades, PHOs were considered GRAS despite growing evidence of trans fat health risks. The FDA did not formally restrict PHOs until 2015, long after the scientific consensus and consumer awareness had shifted (FDA, 2015).

High-Intensity Sweeteners. Stevia and monk fruit sweeteners gained market access partly through GRAS designations based on traditional use in other countries, with limited long-term safety data in Western populations at modern consumption levels.

Titanium Dioxide.Once widely used as a whitening agent and approved as a food additive, titanium dioxide's safety profile came under renewed scrutiny. The EU restricted its use in 2022 based on emerging genotoxicity concerns, while in the U.S., it remained in use through GRAS status (EFSA, 2021).

Plant-Based Ingredients. As food manufacturers have introduced novel plant extracts and fermentation-derived compounds, many have pursued GRAS status to avoid the cost and time of formal approval. Limited long-term data on consumption at scale can exist for these emerging substances.

Why the GRAS Process Is Considered a Loophole

Several structural features of GRAS have led regulators, scientists, and consumer advocates to characterize it as a regulatory gap:

Limited FDA Oversight. The FDA does not independently verify GRAS claims before market entry. Unlike formal additives, which trigger FDA investigation of submitted data, GRAS relies on manufacturer transparency and voluntary notification. The agency has limited resources to audit every GRAS decision after products reach shelves.

Financial Conflict of Interest. Manufacturers fund the expert panels and literature reviews that determine GRAS status. While experts are expected to be objective, the selection and framing of evidence is controlled by the company seeking approval. This differs from independent regulatory assessment.

Inconsistent Scientific Standards. GRAS determinations may be based on limited data—historical use in another country, animal studies alone, or small human populations—without the rigorous toxicology batteries required for formal additives. Standards vary by substance and expert panel.

No Public Input. Unlike formal additive approval, which involves public notice and comment periods, GRAS determinations are often finalized without consumer or stakeholder awareness or input.

Inadequate Long-Term Data.For emerging additives, "safe" use in other contexts or populations may not translate to safety at U.S. consumption levels or over decades of exposure. GRAS determination may precede sufficient real-world use data.

International Perspectives: How Other Regulators Handle Similar Additives

The European Food Safety Authority (EFSA) uses a comparable but more stringent approach. The EFSA requires a formal authorization process for all food additives, with detailed dossier submission, independent assessment, and public consultation (EFSA, 2024). There is no self-determination pathway equivalent to GRAS.

When the EFSA has reviewed substances previously considered safe, it has sometimes restricted or banned them based on reassessment of emerging safety data. Titanium dioxide, E171, was provisionally restricted in 2022 following EFSA evaluation, even though it was long-established in use (EFSA, 2021). This suggests that continuous re-evaluation can catch concerns that initial approval processes might miss.

Canada's approach falls between the U.S. and EU models. The country maintains a list of permitted additives and requires pre-market assessment, but the process is less prescriptive than EFSA's and allows for expedited review of substances with established safety history (Health Canada, 2020).

These international differences highlight that GRAS, while practical, represents a lower bar for regulatory confirmation than some other major markets impose. This creates a situation where substances legal in the U.S. may not be approved in Europe.

Efforts to Reform GRAS and Regulatory Reform Proposals

Both the FDA and Congress have recognized gaps in GRAS oversight. In 2018, the FDA published guidance emphasizing that companies should submit GRAS notices rather than self-determine status, though this remains voluntary (FDA, 2018).

Proposed reforms include:

Mandatory GRAS Notification. Some advocates and lawmakers propose requiring all GRAS determinations be submitted to the FDA before market entry, removing the self-determination option.

Strengthened FDA Review. Enhanced FDA capacity to independently assess GRAS notices, rather than relying primarily on company-submitted data and expert panels.

Public Transparency. Requiring publication of GRAS notices and the scientific basis for determinations, allowing outside experts and the public to comment before market use.

Post-Market Surveillance. Regular re-evaluation of GRAS substances after market introduction to identify emerging safety signals.

Standardized Safety Evidence Requirements. Clearer criteria for what data—animal studies, human trials, epidemiology—should be required before GRAS approval, reducing variation by substance.

As of 2024, no major legislative reform has passed, though the FDA continues to emphasize voluntary notification and has increased scrutiny of novel GRAS substances (FDA, 2023). The balance between regulatory efficiency and safety assurance remains contested.

What This Means for Consumers

Understanding GRAS does not mean avoiding all GRAS additives—many are genuinely safe. Salt, baking soda, and citric acid are GRAS and pose no reasonable concern. However, awareness of how GRAS operates allows consumers to make informed choices:

GRAS Is Not Equivalent to FDA Approval. A GRAS ingredient has not necessarily undergone the same scrutiny as a formally approved additive. If maximum safety assurance is your priority, ingredients approved through the formal additive pathway may provide slightly greater regulatory confidence, though both pathways can yield safe substances.

Novel or Unfamiliar Additives May Have Limited Data. Emerging plant extracts, novel fermentation products, or substances new to the U.S. food supply may have obtained GRAS status based on limited long-term safety data. Reading ingredient labels and researching unfamiliar additives can help you decide if you wish to consume them.

Safety Assessment Is Ongoing, Not One-Time. The FDA monitors adverse event reports and can take action against GRAS substances if safety concerns emerge, as with PHOs. However, post-market surveillance is less intensive than pre-market review.

Transparency Tools Are Limited.The FDA maintains a list of GRAS notices, but not all GRAS determinations are reported. If you want to research an additive's regulatory status, the FDA's GRAS Notice Inventory is a starting point, though it may not capture all GRAS uses (FDA, 2024).

International Markets May Disagree. An additive GRAS in the U.S. might be restricted or banned in Europe or elsewhere. This regulatory divergence reflects different risk tolerances and evidence standards, not necessarily that the U.S. is unsafe or Europe is overly cautious.

Frequently Asked Questions